CTLA4 and uveitis: Among recipients of the ICI monotherapy regimens, the class of anti-PD-1 (HR:1.98 [CI: 1.65-2.37]), and anti-CTLA-4 (HR:5.86 [CI:1.99-17.24]) showed elevated hazard ratios associated with uveitis development compared to their non-ICI comparators.